However, it is not clear whether anti-OPN agents, combined with ICIs, can reverse primary resistance in EGFR mutated NSCLC. Therefore, increased SPP1 expression is consistent with a role in immunosuppression, indicating a possible mechanism through which ICIs is ineffective in EGFR-mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.